Plain-English translation of NCT07243002 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Breast Cancer research guide →This study is learning how ribociclib performs in real-world treatment for people with early-stage breast cancer who have hormone-sensitive tumors. Researchers will gather information from your medical records and ask you to complete surveys and interviews about your experiences with the medication and how it affects your daily life.
While this treatment has been tested in clinical trials, researchers want to understand how well it works and how patients actually experience it when used in regular hospitals and clinics, rather than in controlled research settings.
You likely qualify if…
You likely don't qualify if…
The study will collect information from your medical records about your cancer and treatment over time. You will also be asked to complete questionnaires and possibly participate in interviews about how the medication is affecting you physically and emotionally. The study combines this past medical information with your ongoing feedback as you receive treatment in your regular care setting.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United Kingdom
Sponsor
Novartis Pharmaceuticals
Enrollment target
~3,000 participants
Started
December 2025
Primary completion
April 2030
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.